Menu Search
Equities

Alembic Pharmaceuticals Ltd

APLLTD:NSI

Alembic Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,034.25
  • Today's Change-1.75 / -0.17%
  • Shares traded485.73k
  • 1 Year change+41.10%
  • Beta0.6838
Data delayed at least 15 minutes, as of Nov 12 2024 10:21 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Alembic Pharmaceuticals Ltd grew revenues 10.19% from 56.53bn to 62.29bn while net income improved 80.08% from 3.42bn to 6.16bn.
Gross margin73.84%
Net profit margin10.17%
Operating margin11.59%
Return on assets9.45%
Return on equity13.82%
Return on investment13.32%
More ▼

Cash flow in INRView more

In 2024, Alembic Pharmaceuticals Ltd increased its cash reserves by 59.26%, or 447.30m. The company earned 8.03bn from its operations for a Cash Flow Margin of 12.90%. In addition the company used 3.21bn on investing activities and also paid 4.38bn in financing cash flows.
Cash flow per share47.01
Price/Cash flow per share21.94
Book value per share248.68
Tangible book value per share248.68
More ▼

Balance sheet in INRView more

Alembic Pharmaceuticals Ltd has a Debt to Total Capital ratio of 17.91%, a higher figure than the previous year's 1.51%.
Current ratio1.73
Quick ratio0.8057
Total debt/total equity0.2182
Total debt/total capital0.1791
More ▼

Growth rates in INR

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 37.50% and 80.07%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)1.34%
Div growth rate (5 year)14.87%
Payout ratio (TTM)33.43%
EPS growth(5 years)0.2126
EPS (TTM) vs
TTM 1 year ago		21.59
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.